Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Enzon Pharmaceuticals Inc. (ENZN) had Return on Tangible Equity of -1.91% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.35M |
|
-- |
|
-- |
|
$1.30M |
|
$-1.30M |
|
$0.50M |
|
$-0.81M |
|
$-0.81M |
|
$-0.82M |
|
$-0.82M |
|
$-0.82M |
|
$-0.82M |
|
$-1.30M |
|
$-1.30M |
|
74.22M |
|
74.22M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$43.67M |
|
-- |
|
$0.03M |
|
$43.69M |
|
$0.54M |
|
-- |
|
-- |
|
$0.54M |
|
$-0.92M |
|
$43.15M |
|
$43.15M |
|
74.21M |
|
| Cash Flow Statement Financials | |
$-2.33M |
|
-- |
|
$-1.27M |
|
$46.86M |
|
$43.26M |
|
$-3.60M |
|
-- |
|
-- |
|
$-1.27M |
|
| Fundamental Metrics & Ratios | |
80.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
89.27% |
|
|
Return on Tangible Equity |
-1.91% |
-1.89% |
|
-1.91% |
|
$0.58 |
|
$-0.03 |
|
$-0.03 |
|